2 independent clinical studies - Application of a cream containing 1% BB-BIONT™ for 2 months on hemiface against placebo.
1) 17 female and 1 male volunteers, mean age 32 [20-58]. Combination to oily skin with pockmarks and inflammatory marks.
2) 7 male and 23 female volunteers, mean age 24 [18-39]. Combination to oily skin with pockmarks, inflammatory marks and red or brown post-inflammatory marks.
A healthy skin microbiome:
Cutibacterium acnes after 1 month: -18.5%*/placebo
Staphylococcus epidermidis after 1 month: +15.4%**/placebo
Decrease of inflammatory marks
Number of inflammatory marks: -22%¤¤/placebo. 90% respondents
Number of post-inflammatory marks: -17 %¤¤¤/placebo. 87% respondents.
« I have less inflammatory marks »: 74.1%$ ¤¤/T0.
Soothing of inflammatory marks:
Maximum skin redness: -7%¤¤/placebo. 89% respondents.
Heterogeneity in skin redness: -6.6% ¤¤¤/placebo. 72% respondents.
« I have less post inflammatory marks »: 83%¤¤/T0
Smoothing of pockmarks:
Volume of pockmarks (mm3): -18.9%¤/placebo, 100% respondents.
Skin roughness (mm3), -6.5%¤/placebo, 100% respondents.
Volume of inflammatory marks (mm3) : -34.3%¤¤/placebo, 94% respondents.
Significance:*p<0.067 vs placebo
**non significant vs placebo
¤p<0.01, ¤¤p<0.05, ¤¤¤p<0.08 vs placebo
$ p<0.05/T0
.jpg&mn=beauty&w=768&xr=0&yr=0&xfp=6&yfp=6&hash=52F7E12C58BA54ADFCF156A322CA0BA919C138999FEC74AA)